The Effect of Coronavirus Disease 2019 on Cardiovascular Diseases

Arq Bras Cardiol. 2020 Jun 1;114(5):817-822. doi: 10.36660/abc.20200273.
[Article in English, Portuguese]

Abstract
in English, Portuguese

Coronavirus disease 2019 (COVID-19) is a global pandemic affecting the world, seen in more than 1,300,000 patients. COVID-19 acts through the angiotensin-converting enzyme 2 (ACE2) receptor. Cardiovascular comorbidities are more common with COVID-19, and nearly 10% of cases develop myocarditis (22% of critical patients). Further research is needed to continue or discontinue ACE inhibitors and angiotensin receptor blockers, which are essential in hypertension and heart failure in COVID-19. Intensive research is promising for the treatment and prevention of COVID-19.

A doença de coronavírus 2019 (COVID-19) é uma pandemia global afetando o mundo, estando presente em mais de 1.300.000 pacientes. O COVID-19 age pelo receptor da enzima conversora de angiotensina 2 (ECA2). As comorbidades cardiovasculares são mais frequentes com COVID-19, e cerca 10% de casos desenvolvem miocardite (22% de pacientes críticas). Mais pesquisas serão necessárias para continuar ou descontinuar inibidores de ECA e bloqueadores dos receptores da angiotensina, que são essenciais para hipertensão e insuficiência cardíaca em COVID-19. Pesquisa intensiva é promissora para o tratamento e a prevenção da COVID-19.

Publication types

  • Review

MeSH terms

  • Angiotensin Receptor Antagonists / metabolism
  • Angiotensin-Converting Enzyme 2
  • Animals
  • Antirheumatic Agents / therapeutic use
  • Antiviral Agents / therapeutic use
  • Betacoronavirus*
  • COVID-19
  • Cardiovascular Diseases / enzymology
  • Cardiovascular Diseases / epidemiology*
  • Cardiovascular Diseases / mortality
  • China / epidemiology
  • Chloroquine / therapeutic use
  • Comorbidity
  • Coronavirus Infections / drug therapy
  • Coronavirus Infections / enzymology
  • Coronavirus Infections / epidemiology*
  • Coronavirus Infections / mortality
  • Humans
  • Hypertension / enzymology
  • Hypertension / epidemiology
  • Pandemics
  • Peptidyl-Dipeptidase A / metabolism
  • Pneumonia, Viral / drug therapy
  • Pneumonia, Viral / enzymology
  • Pneumonia, Viral / epidemiology*
  • Pneumonia, Viral / mortality
  • SARS-CoV-2

Substances

  • Angiotensin Receptor Antagonists
  • Antirheumatic Agents
  • Antiviral Agents
  • Chloroquine
  • Peptidyl-Dipeptidase A
  • ACE2 protein, human
  • Angiotensin-Converting Enzyme 2